Investigating Aberrant Results in Microbiological Examination of Nonsterile Product Assays

References

1. 1.↵
   U.S. Pharmacopeial Convention, General Chapter <61> Microbiological Examination of Nonsterile Products: Microbial Enumeration Tests. In USP 42–NF 37, USP: Rockville, MD, 2019.
2. 2.↵
   Council of Europe, Microbiological Examination of Nonsterile Products: Microbial Enumeration Tests, Chapter 2.6.12. In European Pharmacopoeia (Ph. Eur.), 9th Edition, Council of Europe: Strasbourg, France, 2017.
3. 3.↵
   Ministry of Health Labour and Welfare of Japan, General Tests, Processes and Apparatus—4.05 Microbiological Examination of Non-sterile Products. In The Japanese Pharmacopoeia, 17th Edition (English Version), MHLW: Tokyo, 2016.
4. 4.↵
   U.S. Pharmacopeial Convention, General Chapter <62> Microbiological Examination of Nonsterile Products: Tests for Specified Microorganisms. In USP 42–NF 37, USP: Rockville, MD, 2019.
5. 5.↵
   Council of Europe, Microbiological Examination of Nonsterile Products: Tests for Specified Micro-organisms, Chapter EP 2.6.13. In European Pharmacopoeia (Ph. Eur.), 9th Edition, Council of Europe: Strasbourg, France, 2017.
6. 6.↵
   U.S. Food and Drug Administration, 21 CFR Part 211–Current Good Manufacturing Practice for Finished Pharmaceuticals. FDA Web site https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=211. (accessed June 17, 2019).
7. 7.↵
   U.S. Pharmacopeial Convention, General Chapter <1111> Microbiological Examination of Nonsterile Products: Acceptance Criteria for Pharmaceutical Preparations and Substances for Pharmaceutical Use. In USP 42–NF 37, USP: Rockville, MD, 2019.
8. 8.↵
   International Council for Harmonisation, Quality Guideline Q6A: Decision Trees 6 and 8. ICH Web site. https://database.ich.org/sites/default/files/Q6A_Decision_Tree.pdf (accessed Sept 20, 2019).
9. 9.↵
   Pharmaceutical Microbiology Manual, 2014. FDA Web site. https://www.fda.gov/files/about%20fda/published/Pharmaceutical-Microbiology-Manual.pdf (accessed Sept 20, 2019).
10. 10.↵
    Parenteral Drug Association Inc. Technical Report No. 67: Exclusion of Objectionable Microorganisms from Nonsterile Pharmaceuticals, Medical Devices, and Cosmetics; Bethesda, MD, 2014.
11. 11.↵
    U.S. Pharmacopeial Convention, General Chapter <60> Microbiological Examination of Nonsterile Products—Tests for Burkholderia cepacia Complex. Pharmacopeial Forum [Online] 2018, 44, 5. http://www.usppf.com/pf/pub/index.html (accessed on Sept 20, 2019).
12. 12.↵
    U.S. Food and Drug Administration, Guidance for Industry: Investigating Out-of-Specification Test Results for Pharmaceutical Production. Center for Biologics Evaluation and Research. U.S. Department of Health and Human Services: Rockville, MD, 2006.
13. 13.↵
    1. Sutton S.

    Successful Microbiological Investigations. Am. Pharm. Rev. [Online] 2011. https://www.americanpharmaceuticalreview.com/Featured-Articles/37190-Successful-Microbiological-Investigations/ (accessed June 18, 2019).
14. 14.↵
    1. Carmody J.

    7 Steps to Properly Navigate an Event Investigation. Pharmaceutical Online [Online] 2017. https://www.pharmaceuticalonline.com/doc/steps-to-properly-navigate-an-event-investigation-0001 (accessed June 17, 2019).
15. 15.↵
    U.S. Pharmacopeial Convention, General Chapter <1117> Microbiological Best Laboratory Practices. In USP 42–NF 37, USP: Rockville, MD, 2019.
16. 16.↵
    Cause Analysis Tools. ASQ Web site. https://asq.org/quality-resources/root-cause-analysis/tools (accessed June 17, 2019).